A Compliant Abbott Channels More Funds Into Core Diagnostics R&D
This article was originally published in The Gray Sheet
Executive Summary
Now that Abbott is in the final throes of a 1999 FDA consent degree, the company's core chemistry and immunoassay diagnostics unit says it has freed up some more funds for research and development
You may also be interested in...
FDA Panel Recommends New Studies For Fujirebio’s Ovarian Cancer Test
FDA should not clear Fujirebio's HE4 enzyme immunoassay kit and associated "risk of ovarian malignancy algorithm"(ROMA) until the firm demonstrates the test's ability to help community physicians triage patients for referral to gynecologic oncology specialists, according to the agency's Immunology Devices advisory panel
Abbott’s Recommitment To Core Diagnostics Is Rewarded By Strong Returns
Abbott has a newfound loyalty to its long-struggling core diagnostics business, which the company was at the brink of unloading just last year, and the division has responded with a dramatic turnaround
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”